Trial · NCT02249949

Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery

NCT02249949, Phase 2, Completed, Alliance for Clinical Trials in Oncology; results first posted 2019-06-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery. Trials, record NCT02249949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02249949

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
NCT number: NCT02249949
Status: Completed
Phases: Phase 2
Enrollment: 15 participants, actual
Lead sponsor: Alliance for Clinical Trials in Oncology
Conditions: Liposarcoma
Interventions: efatutazone
First posted: 2014-09-26
Last updated: 2025-01-27
Results first posted: 2019-06-27

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Confirmed Overall Response Rate Per the RECIST 1.1 Criteria	Up to 24 weeks (8 cycles)	The response rate (percentage) is the percent of patients whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.
Secondary	Progression Free Survival (PFS) Determined Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	Time from study entry to the first of either disease progression or death from any cause, assessed up to 5 years	Progression free survival (PFS) is defined as the time from study entry to the date of disease progression or death resulting from any cause, whichever comes first. Progression is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
Secondary	Overall Survival	Time from study entry to death from any cause, assessed up to 5 years	Overall survival time is defined as the time from study entry to death due to any cause. The median and 95% confidence intervals are estimated using the Kaplan-Meier estimator.
Secondary	Incidence of Grade 3+ Adverse Events Summarized Using Common Terminology Criteria for Adverse Events Version 4.0	Up to 5 years	Incidence of grade 3+ adverse events summarized using Common Terminology Criteria for Adverse Events version 4.0: The frequency and percentage of grade 3+ adverse events will be estimated

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Confirmed Overall Response Rate Per the RECIST 1.1 Criteria	Up to 24 weeks (8 cycles)	percentage of patients	NUMBER
SECONDARY	Progression Free Survival (PFS) Determined Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	Time from study entry to the first of either disease progression or death from any cause, assessed up to 5 years	months	MEDIAN
SECONDARY	Overall Survival	Time from study entry to death from any cause, assessed up to 5 years	months	MEDIAN
SECONDARY	Incidence of Grade 3+ Adverse Events Summarized Using Common Terminology Criteria for Adverse Events Version 4.0	Up to 5 years	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Confirmed Overall Response Rate Per the RECIST 1.1 Criteria	Efatutazone Dihydrochloride		0	95% Confidence Interval 0 to 28	percentage of patients
Progression Free Survival (PFS) Determined Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1	Efatutazone Dihydrochloride		1.4	95% Confidence Interval 1.2 to NA	months
Overall Survival	Efatutazone Dihydrochloride		8.6	95% Confidence Interval 6.8 to NA	months
Incidence of Grade 3+ Adverse Events Summarized Using Common Terminology Criteria for Adverse Events Version 4.0	Efatutazone Dihydrochloride	at least one grade 3 or worse AE	6		Participants
Incidence of Grade 3+ Adverse Events Summarized Using Common Terminology Criteria for Adverse Events Version 4.0	Efatutazone Dihydrochloride	at least one grade 4 or worse AE	3		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Efatutazone Dihydrochloride	13
Overall Study	COMPLETED	Efatutazone Dihydrochloride	11
Overall Study	NOT COMPLETED	Efatutazone Dihydrochloride	2

Source ClinicalTrials.gov

Adverse events52

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Efatutazone Dihydrochloride	6	11	19
other	Blood and lymphatic system disorders - Other, specify	Blood and lymphatic system disorders	Efatutazone Dihydrochloride	1	11	1
other	Constipation	Gastrointestinal disorders	Efatutazone Dihydrochloride	1	11	1
other	Diarrhea	Gastrointestinal disorders	Efatutazone Dihydrochloride	1	11	1
other	Nausea	Gastrointestinal disorders	Efatutazone Dihydrochloride	3	11	4
other	Vomiting	Gastrointestinal disorders	Efatutazone Dihydrochloride	1	11	1
other	Edema face	General disorders	Efatutazone Dihydrochloride	1	11	2
other	Edema limbs	General disorders	Efatutazone Dihydrochloride	8	11	26
other	Edema trunk	General disorders	Efatutazone Dihydrochloride	1	11	1
other	Fatigue	General disorders	Efatutazone Dihydrochloride	7	11	21

1 to 10 of 52Source ClinicalTrials.gov

See all 52 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Efatutazone Dihydrochloride	8	11
Total, other adverse events	Efatutazone Dihydrochloride	11	11
Total, serious adverse events	Efatutazone Dihydrochloride	6	11

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02249949

GET https://conductscience.org/api/trials/v1/NCT02249949/events?page=2

API reference For AI assistants